Keith L Knutson Selected Research

Keith L Knutson Research Topics

Disease

74	Neoplasms (Cancer) 05/2024 - 01/2002
30	Ovarian Neoplasms (Ovarian Cancer) 01/2024 - 06/2002
28	Breast Neoplasms (Breast Cancer) 04/2024 - 01/2002
6	COVID-19 02/2024 - 01/2022
5	Rheumatoid Arthritis 01/2020 - 06/2010
4	Melanoma (Melanoma, Malignant) 04/2024 - 01/2002
4	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/2024 - 01/2022
4	Infections 12/2018 - 10/2011
4	Carcinoma (Carcinomatosis) 04/2014 - 04/2006
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 08/2002
3	Disease Progression 07/2017 - 07/2006
3	Inflammation (Inflammations) 10/2013 - 06/2009
3	Prostatic Neoplasms (Prostate Cancer) 06/2010 - 08/2002
2	Experimental Melanoma 04/2024 - 01/2020
2	Rheumatic Diseases (Rheumatism) 03/2023 - 01/2023
2	Breast Diseases (Breast Disease) 01/2023 - 01/2018
2	Adenocarcinoma of Lung 11/2022 - 01/2019
2	Carcinogenesis 01/2018 - 02/2014
2	Ovarian Epithelial Carcinoma 06/2009 - 03/2008
2	Glioblastoma (Glioblastoma Multiforme) 07/2003 - 08/2002
1	Myositis (Idiopathic Inflammatory Myopathies) 03/2023
1	Sjogren's Syndrome (Sjogren Syndrome) 03/2023
1	Ankylosing Spondylitis 03/2023
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/2023
1	Psoriatic Arthritis 03/2023
1	Autoimmune Diseases (Autoimmune Disease) 01/2023
1	Breakthrough Infections 04/2022
1	Cytopenia 04/2022
1	Hematologic Neoplasms (Hematological Malignancy) 04/2022
1	Triple Negative Breast Neoplasms 01/2020
1	Adenocarcinoma 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2019
1	Eosinophilia 01/2019
1	Lymphoma (Lymphomas) 11/2018

Drug/Important Bio-Agent (IBA)

28	VaccinesIBA 11/2023 - 01/2002
19	AntigensIBA 10/2020 - 08/2002
17	Proteins (Proteins, Gene)FDA Link 05/2024 - 04/2002
16	Peptides (Polypeptides)IBA 12/2018 - 04/2002
13	Neoplasm Antigens (Tumor Antigens)IBA 01/2018 - 06/2002
12	EpitopesIBA 01/2020 - 07/2002
11	Biomarkers (Surrogate Marker)IBA 04/2024 - 07/2009
11	CytokinesIBA 01/2020 - 04/2006
9	Immune Checkpoint InhibitorsIBA 05/2024 - 11/2018
8	Monoclonal AntibodiesIBA 04/2024 - 02/2004
8	Messenger RNA (mRNA)IBA 02/2024 - 06/2014
7	Trastuzumab (Herceptin)FDA Link 10/2022 - 06/2010
6	Folate Receptor 1IBA 01/2020 - 09/2006
6	AntibodiesIBA 01/2020 - 01/2002
5	Interleukin-10 (Interleukin 10)IBA 12/2017 - 04/2008
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2011 - 05/2002
4	DNA (Deoxyribonucleic Acid)IBA 05/2024 - 06/2010
4	mRNA VaccinesIBA 02/2024 - 04/2022
4	Interleukin-2 (IL2)IBA 01/2017 - 07/2006
4	HLA-DR Antigens (HLA-DR)IBA 02/2010 - 01/2006
4	EnzymesIBA 02/2010 - 05/2002
3	LigandsIBA 05/2024 - 06/2011
3	RNA (Ribonucleic Acid)IBA 12/2018 - 01/2012
3	Protein Subunit VaccinesIBA 01/2018 - 01/2003
3	Interleukin-8 (Interleukin 8)IBA 01/2017 - 10/2011
3	Cancer VaccinesIBA 12/2015 - 01/2006
3	Transcription Factors (Transcription Factor)IBA 07/2014 - 06/2009
3	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2013 - 05/2002
3	ImmunosorbentsIBA 02/2010 - 05/2002
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2024 - 07/2011
2	COVID-19 VaccinesIBA 02/2024 - 01/2022
2	Hormones (Hormone)IBA 10/2022 - 08/2002
2	Estrogen ReceptorsIBA 11/2020 - 10/2006
2	Indicators and Reagents (Reagents)IBA 01/2017 - 04/2007
2	ChemokinesIBA 01/2017 - 01/2012
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2015 - 07/2011
2	invariant chain (Ii-Key)IBA 07/2011 - 01/2006
2	Folic Acid (Vitamin M)FDA LinkGeneric 07/2011 - 03/2008
2	NF-kappa B (NF-kB)IBA 05/2011 - 06/2009
2	flt3 ligand protein (flt3 ligand)IBA 01/2003 - 04/2002
1	Oncogene Proteins (Oncogene Protein)IBA 04/2024
1	Rituximab (Mabthera)FDA Link 03/2023
1	Protein Kinases (Protein Kinase)IBA 11/2022
1	B7-H1 AntigenIBA 11/2022
1	Auranofin (Ridaura)FDA Link 11/2022
1	ErbB Receptors (EGF Receptor)IBA 10/2022
1	Cyclin-Dependent Kinase 4IBA 04/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	pembrolizumabIBA 01/2020
1	margetuximabIBA 01/2020
1	durvalumabIBA 01/2020
1	Rheumatoid FactorIBA 01/2020
1	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 01/2020
1	B 31IBA 01/2019
1	NivolumabIBA 01/2019
1	Chimeric Antigen ReceptorsIBA 12/2018
1	Tumor Biomarkers (Tumor Markers)IBA 12/2018
1	micaIBA 01/2018

Therapy/Procedure

37	Therapeutics 05/2024 - 07/2003
21	Immunotherapy 05/2024 - 01/2002
7	Drug Therapy (Chemotherapy) 04/2022 - 01/2004
1	Neoadjuvant Therapy 01/2024
1	Prophylactic Mastectomy 01/2023
1	Hyperthermic Intraperitoneal Chemotherapy 01/2021
1	Cytoreduction Surgical Procedures 01/2021